positions available now

Category Archives: PBAC

PBAC Meeting Outcomes – July 2018

The July 2018 PBAC Meeting Outcomes were published on 17th August 2018. With 64 outcomes in total, the Commercial Eyes Market Access team provides an overview of PBAC decision making, including additional analysis conducted on biosimilar and oncology submissions.   … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged , , | Comments Off on PBAC Meeting Outcomes – July 2018

Public Submissions to the August 2018 PBAC Special Meeting – Part 2

In the second part of this two-part series (Read Part 1 about here) we bring you further insight into opinions from the public submissions to the August 2018 PBAC Special Meeting. Opinions from the Public Submissions Outcomes of the PBAC’s … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , , , , | Comments Off on Public Submissions to the August 2018 PBAC Special Meeting – Part 2

Public Submissions to the August 2018 PBAC Special Meeting – Part 1

In the first of a two-part series, we provide insights into opinions from 28 public submissions to the August 2018 PBAC Special Meeting held on 17 August 2018 regarding considerations for PD-1 and PD-L1 checkpoint inhibitors for multiple cancer types … Continue reading

Posted in Market Access, PBAC, PBS, Uncategorized | Tagged , , , , | Comments Off on Public Submissions to the August 2018 PBAC Special Meeting – Part 1

PBAC Special Meeting – August 2018

The August 2018 PBAC special meeting is scheduled for 17 August 2018 to consider options for listing PD-1 and PD-L1 checkpoint inhibitors for the treatment of multiple tumours (pan-tumour indications) on the PBS. Here, the Commercial Eyes Market Access team … Continue reading

Posted in Market Access, PBAC | Tagged , , , , , | Comments Off on PBAC Special Meeting – August 2018

The long road to PBS listing for Orkambi

Orkambi (lumacaftor and ivacaftor), a treatment for cystic fibrosis (CF), will go before the PBAC for a fourth time at the upcoming July 2018 PBAC meeting. So far, the road to reimbursement has been filled with multiple rejections, a strong … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, PBS | Tagged , , , | Comments Off on The long road to PBS listing for Orkambi

PBAC Meeting Agenda – July 2018

The July 2018 PBAC Meeting is scheduled from 4 to 6 Jul 2018. Here, the Commercial Eyes Market Access team provides an overview of the meeting agenda, including submissions relating to biosimilars lodged for this meeting.     The Commercial … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged , , , , | Comments Off on PBAC Meeting Agenda – July 2018

PBAC Meeting Agenda – March 2018

  The Commercial Eyes Market Access can help you navigate Australia and New Zealand’s sophisticated and mature systems of Health Technology Assessment. Contact us on (03) 9251 0777 to learn more about our PBAC Outcomes Database and let us help … Continue reading

Posted in Market Insight, PBAC | Tagged , | Comments Off on PBAC Meeting Agenda – March 2018

PBAC outcomes: a snapshot of 2017

  The Commercial Eyes Market Access Team can help you navigate Australia and New Zealand’s sophisticated and mature systems of Health Technology Assessment. Contact us on (03) 9251 0777 to learn more about our PBAC Outcomes Database and let us … Continue reading

Posted in Market Access, PBAC | Tagged , , | Comments Off on PBAC outcomes: a snapshot of 2017

Ready? Get Set…Go! Planning the most appropriate strategy for your product to enter the Australian market

As we weave our way through life, we plan…plan our career, plan our finances, plan a holiday and most of us would have at least once in our lifetime planned a party. The key to a successful plan is finding … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC, Regulatory Services, TGA | Tagged , | Comments Off on Ready? Get Set…Go! Planning the most appropriate strategy for your product to enter the Australian market

Multi-criteria decision making – How can non-health attributes be considered and valued?

Pressure is mounting on decisions to recommend and continue funding health technologies. Concerns around the rising cost of new medicines, an ageing population with greater resource utilisation, federal and state healthcare budgetary constraints, and an increasing dependency ratio (the ratio … Continue reading

Posted in Life Sciences Industry, Market Access, PBAC | Tagged | Comments Off on Multi-criteria decision making – How can non-health attributes be considered and valued?
Copyright © 2014 Commercial Eyes